Latest Headlines

Latest Headlines

Harvard, AstraZeneca partner to replace animal testing with 'organs-on-chips'

AstraZeneca has partnered with the Wyss Institute to use its organs-on-chips technology--miniature human organs made of a clear, flexible polymer that contain tiny tubes lined with living human cells--to help improve the way it tests drugs for humans.

DoD ponies up $15M to develop Terumo's blood-cleaning tech

Terumo BCT, the blood-focused division of the Japanese med tech giant, has signed a deal with the U.S. Department of Defense to share costs in the development of a device that can treat donated blood used in emergency transfusions.

Novella teams with Scioderm for 'breakthrough' drug

Novella Clinical has snagged its first high-profile partnership since being bought by CRO giant Quintiles, teaming up with biotech Scioderm to manage a mid-stage trial of the company's rare skin disease treatment.

Stallergenes forges $198M pact for allergy R&D

France's Stallergenes has inked a deal worth up to $198 million with biotech DBV Technologies, partnering with the company to develop a treatment for birch allergy.

AstraZeneca, Harvard partner to advance 'organs-on-chips' drug-testing tech

AstraZeneca has teamed up with Harvard University's Wyss Institute for Biologically Inspired Engineering to use the institute's "organs-on-chips" technology--miniature human organs made by 3D printing--to improve the way it tests drugs for humans.

Amgen taps KineMed for Alzheimer's biomarkers

Drug developer Amgen has reached out to KineMed with an eye on neurodegenerative biomarkers, paying to use the California biotech's platform to ferret out the causes of brain cell-killing disorders like Alzheimer's disease.

Evotec gets $5.4M from Boehringer Ingelheim in cancer research pact

Germany-based Evotec AG has advanced an oncology molecule into preclinical development, raking in a €4 million ($5.4 million) milestone payment from partner Boehringer Ingelheim under a research pact.

Merck KGaA scouts for deep-pocketed partners to leverage its R&D budget

The head of the pharma division, Stefan Oschmann, tells the Financial Times that the Darmstadt-based drug developer is looking to stretch its $1.5 billion annual research budget with some additional cost-sharing deals that might include private equity groups as well as other industry partners.

Quintiles snags registry deal with Muscular Dystrophy Association

Quintiles is lending its research and analytics expertise to the Muscular Dystrophy Association, signing a deal to develop a massive registry of patient data that could help investigators develop new therapies.

Parexel looks to Japan for eClinical growth

Parexel International has inked a deal to pool its clinical trial data management service with a Japanese provider, teaming up to expand its share of the local market.